vs
GENMAB A/S（GMAB）与ROKU, INC（ROKU）财务数据对比。点击上方公司名可切换其他公司
ROKU, INC的季度营收约是GENMAB A/S的1.5倍（$1.4B vs $925.0M），GENMAB A/S净利率更高（36.3% vs 5.8%，领先30.6%），GENMAB A/S同比增速更快（18.7% vs 16.1%），GENMAB A/S自由现金流更多（$327.0M vs $106.6M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
Roku是美国流媒体技术企业，2002年由安东尼·伍德创立，主营数字媒体播放器、电视硬件生产，流媒体内容分发及平台广告运营。截至2024年覆盖用户达1.45亿，是美国流媒体视频分发领域的市场领导者，业务覆盖澳、加、法、德、英及拉美多国。
GMAB vs ROKU — 直观对比
营收规模更大
ROKU
是对方的1.5倍
$925.0M
营收增速更快
GMAB
高出2.6%
16.1%
净利率更高
GMAB
高出30.6%
5.8%
自由现金流更多
GMAB
多$220.4M
$106.6M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $1.4B |
| 净利润 | $336.0M | $80.5M |
| 毛利率 | 93.8% | 43.5% |
| 营业利润率 | 38.9% | 4.7% |
| 净利率 | 36.3% | 5.8% |
| 营收同比 | 18.7% | 16.1% |
| 净利润同比 | 65.5% | 326.4% |
| 每股收益（稀释后） | $5.42 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABROKU
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $925.0M | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | $779.0M | $968.2M | ||
| Q1 24 | — | $881.5M |
净利润GMABROKU
| Q4 25 | — | $80.5M | ||
| Q3 25 | — | $24.8M | ||
| Q2 25 | $336.0M | $10.5M | ||
| Q1 25 | — | $-27.4M | ||
| Q4 24 | — | $-35.5M | ||
| Q3 24 | — | $-9.0M | ||
| Q2 24 | $203.0M | $-34.0M | ||
| Q1 24 | — | $-50.9M |
毛利率GMABROKU
| Q4 25 | — | 43.5% | ||
| Q3 25 | — | 43.4% | ||
| Q2 25 | 93.8% | 44.8% | ||
| Q1 25 | — | 43.6% | ||
| Q4 24 | — | 42.7% | ||
| Q3 24 | — | 45.2% | ||
| Q2 24 | 96.4% | 43.9% | ||
| Q1 24 | — | 44.1% |
营业利润率GMABROKU
| Q4 25 | — | 4.7% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | 38.9% | -2.1% | ||
| Q1 25 | — | -5.7% | ||
| Q4 24 | — | -3.3% | ||
| Q3 24 | — | -3.4% | ||
| Q2 24 | 30.3% | -7.4% | ||
| Q1 24 | — | -8.2% |
净利率GMABROKU
| Q4 25 | — | 5.8% | ||
| Q3 25 | — | 2.0% | ||
| Q2 25 | 36.3% | 0.9% | ||
| Q1 25 | — | -2.7% | ||
| Q4 24 | — | -3.0% | ||
| Q3 24 | — | -0.9% | ||
| Q2 24 | 26.1% | -3.5% | ||
| Q1 24 | — | -5.8% |
每股收益（稀释后）GMABROKU
| Q4 25 | — | $0.55 | ||
| Q3 25 | — | $0.16 | ||
| Q2 25 | $5.42 | $0.07 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | — | $-0.24 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | $3.13 | $-0.24 | ||
| Q1 24 | — | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $2.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3B | $2.7B |
| 总资产 | $6.5B | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMABROKU
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | $1.3B | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | $622.0M | $2.1B | ||
| Q1 24 | — | $2.1B |
股东权益GMABROKU
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | $5.3B | $2.6B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | $4.4B | $2.4B | ||
| Q1 24 | — | $2.4B |
总资产GMABROKU
| Q4 25 | — | $4.4B | ||
| Q3 25 | — | $4.4B | ||
| Q2 25 | $6.5B | $4.3B | ||
| Q1 25 | — | $4.2B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | — | $4.3B | ||
| Q2 24 | $5.6B | $4.1B | ||
| Q1 24 | — | $4.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $107.7M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $106.6M |
| 自由现金流率自由现金流/营收 | 35.4% | 7.6% |
| 资本支出强度资本支出/营收 | 2.4% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.04× | 1.34× |
| 过去12个月自由现金流最近4个季度 | — | $478.4M |
8季度趋势，按日历期对齐
经营现金流GMABROKU
| Q4 25 | — | $107.7M | ||
| Q3 25 | — | $127.6M | ||
| Q2 25 | $349.0M | $109.7M | ||
| Q1 25 | — | $138.7M | ||
| Q4 24 | — | $79.3M | ||
| Q3 24 | — | $68.7M | ||
| Q2 24 | $438.0M | $23.4M | ||
| Q1 24 | — | $46.7M |
自由现金流GMABROKU
| Q4 25 | — | $106.6M | ||
| Q3 25 | — | $126.5M | ||
| Q2 25 | $327.0M | $108.6M | ||
| Q1 25 | — | $136.8M | ||
| Q4 24 | — | $76.8M | ||
| Q3 24 | — | $67.6M | ||
| Q2 24 | $430.0M | $22.5M | ||
| Q1 24 | — | $46.0M |
自由现金流率GMABROKU
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 10.4% | ||
| Q2 25 | 35.4% | 9.8% | ||
| Q1 25 | — | 13.4% | ||
| Q4 24 | — | 6.4% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | 55.2% | 2.3% | ||
| Q1 24 | — | 5.2% |
资本支出强度GMABROKU
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | 2.4% | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | 1.0% | 0.1% | ||
| Q1 24 | — | 0.1% |
现金转化率GMABROKU
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 5.14× | ||
| Q2 25 | 1.04× | 10.45× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
ROKU
| Services | $1.2B | 88% |
| Products | $170.9M | 12% |
